Nynomic AG
Original-Research: Nynomic AG (von NuWays AG): Kaufen

Original-Research: Nynomic AG – from NuWays AG

Classification of NuWays AG to Nynomic AG

Company Name: Nynomic AG
ISIN: DE000A0MSN11

Reason for the research: Update
Recommendation: Kaufen
from: 10.05.2024
Target price: EUR 52.00
Target price on sight of: 12 Monaten
Last rating change:
Analyst: Christian Sandherr

Solid start into FY24 despite challenging end markets

Topic: Nynomic published a solid start into the year with order intake
returning to growth for the first time since Q3 2022. Similar to FY23, this
year’s operational performance should again be back-end loaded.

Preliminary Q1 sales grew by 6.5% yoy to € 23m thanks to consolidation
effects from last year’s acquisitions of NLIR and art photonics (eNuW +4.5%
yoy growth) as well as solid demand across the group’s portfolio companies,
despite a weak industry momentum. At the same time, Q1 EBIT stood at €
1.6m, up 6.7% yoy, with a margin of roughly 7%. Mind you, the low margin
(in comparison to FY margin of >13%) is due to the seasonallity of the
business, a changing product mix and limited op. leverage.

Importantly, order intake returned to growth for the first time since Q3
2022. It grew by 24% yoy and 57% qoq to € 28.7m. This does not yet include
the high single-digit €m order (eNuW: € 7-8m) that the company received at
the end of April (solution to further improve the efficiency and accuracy
of the customer’s gas analysis); order backlog +11% qoq to € 59.6m. This
should provide additional visibility regarding the mentioned sequential
improvements throughout the year.

Similar to FY23, management again expects further operational improvements
in the second quarter, followed by a particularly strong second half of the
year (in FY23, H2 accounted for 55% of FY sales and 70% of FY EBIT) due to
the known lumpy nature of the business.

For FY24e, management continues to expect “at least single-digit percentage
growth” and a further EBIT margin improvement, which compares to our
estimates of 12% yoy sales growth (8% organic) and a 60bps EBIT margin
improvement based on (1) unbroken demand from semi customers, (2)
fulfilment precision farming orders, (3) TactiScan gaining traction, (4) a
structurally growing medtech market and (5) new product launches such as
LabScanner Plus.

Acquisitions could serve as additional catalyst. As per its growth
strategy, Nynomic should be looking to acquire 1-2 companies (technological
and geographical diversification) during the next six months. Thanks to its
strong balance sheet, we also regard bigger targets (~ € 20m sales) as
possible.

We confirm our BUY rating with an unchanged € 52 PT based on DCF and keep
the stock on our Alpha List.

You can download the research here:
http://www.more-ir.de/d/29653.pdf
For additional information visit our website
www.nuways-ag.com/research.

Contact for questions
NuWays AG – Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++

——————-transmitted by EQS Group AG.——————-


The issuer is solely responsible for the content of this research.
The result of this research does not constitute investment advice
or an invitation to conclude certain stock exchange transactions.